IL216804A0 - Methods for treating chronic kidney disease - Google Patents
Methods for treating chronic kidney diseaseInfo
- Publication number
- IL216804A0 IL216804A0 IL216804A IL21680411A IL216804A0 IL 216804 A0 IL216804 A0 IL 216804A0 IL 216804 A IL216804 A IL 216804A IL 21680411 A IL21680411 A IL 21680411A IL 216804 A0 IL216804 A0 IL 216804A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- kidney disease
- chronic kidney
- treating chronic
- treating
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18493709P | 2009-06-08 | 2009-06-08 | |
| US23538109P | 2009-08-20 | 2009-08-20 | |
| PCT/US2010/037565 WO2010144336A2 (en) | 2009-06-08 | 2010-06-07 | Methods for treating chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL216804A0 true IL216804A0 (en) | 2012-02-29 |
Family
ID=43309421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL216804A IL216804A0 (en) | 2009-06-08 | 2011-12-06 | Methods for treating chronic kidney disease |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8637482B2 (enExample) |
| EP (2) | EP2440214A4 (enExample) |
| JP (1) | JP2012529430A (enExample) |
| CN (1) | CN102458418B (enExample) |
| CA (1) | CA2763537A1 (enExample) |
| DK (1) | DK3276004T3 (enExample) |
| IL (1) | IL216804A0 (enExample) |
| WO (1) | WO2010144336A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| AU2012223366B2 (en) | 2011-03-03 | 2017-02-23 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US9631170B2 (en) | 2011-10-06 | 2017-04-25 | University Of Wyoming | Genetically inducible hydrogen peroxide resistance and production |
| ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
| US9546364B2 (en) | 2013-03-15 | 2017-01-17 | Carnegie Mellon University | Synthetic lariat RNA for RNA interference |
| CN104073517A (zh) * | 2013-03-28 | 2014-10-01 | 卫生部北京医院 | p66Shc重组腺病毒载体及构建和应用 |
| MX391220B (es) * | 2013-05-14 | 2025-03-21 | Metabolon Inc | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. |
| SI3444349T1 (sl) * | 2014-05-29 | 2021-07-30 | Quark Pharmaceuticals, Inc. | Postopki in sestavki za preprečevanje ishemične reperfuzijske poškodbe v organih |
| GB201413081D0 (en) * | 2014-07-23 | 2014-09-03 | Univ Birmingham | Markers for AF |
| ES2627997B1 (es) * | 2015-09-18 | 2018-05-21 | Fundación Instituto De Investigación Sanitaria Fundación Jiménez Díaz | Uso de una composición farmacéutica para la fabricación de un medicamento para el tratamiento y/o la prevención del daño renal agudo |
| EP4442200A3 (en) | 2016-04-01 | 2024-12-04 | Cardiac Pacemakers, Inc. | Multi-disease patient management |
| WO2018027149A1 (en) * | 2016-08-04 | 2018-02-08 | University Of Miami | Methods of treating alport syndrome |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11771113B2 (en) | 2017-05-31 | 2023-10-03 | Mars, Incorporated | Methods of diagnosing and treating chronic kidney disease |
| CN116726173B (zh) * | 2022-03-03 | 2025-09-23 | 浙江大学 | Trpm2抑制剂的用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| CA2467936C (en) | 2001-11-21 | 2013-11-05 | Mitsubishi Chemical Corporation | Method of inhibiting gene expression |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
| JP4991547B2 (ja) | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| US8362229B2 (en) | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| US20080090765A1 (en) | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| WO2008042012A1 (en) * | 2006-10-05 | 2008-04-10 | Rhode Island Hospital | Compositions and methods for detecting and treating renal injury and inflammation |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| EP2137205A2 (en) * | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| WO2009032915A2 (en) * | 2007-09-06 | 2009-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arrays, kits and cancer characterization methods |
| CA2701845A1 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US20090226547A1 (en) | 2008-03-05 | 2009-09-10 | Gilbard Jeffrey P | Dietary Supplement For Eye Health |
| WO2009116037A2 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
-
2010
- 2010-06-07 US US13/376,766 patent/US8637482B2/en active Active
- 2010-06-07 JP JP2012514218A patent/JP2012529430A/ja active Pending
- 2010-06-07 EP EP10786615.4A patent/EP2440214A4/en not_active Withdrawn
- 2010-06-07 CN CN201080028245.5A patent/CN102458418B/zh not_active Expired - Fee Related
- 2010-06-07 WO PCT/US2010/037565 patent/WO2010144336A2/en not_active Ceased
- 2010-06-07 DK DK17190227.3T patent/DK3276004T3/da active
- 2010-06-07 CA CA2763537A patent/CA2763537A1/en not_active Abandoned
- 2010-06-07 EP EP17190227.3A patent/EP3276004B1/en active Active
-
2011
- 2011-12-06 IL IL216804A patent/IL216804A0/en unknown
-
2014
- 2014-01-27 US US14/165,249 patent/US20140140922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3276004A2 (en) | 2018-01-31 |
| CA2763537A1 (en) | 2010-12-16 |
| EP3276004B1 (en) | 2020-03-18 |
| WO2010144336A3 (en) | 2011-02-03 |
| WO2010144336A2 (en) | 2010-12-16 |
| US8637482B2 (en) | 2014-01-28 |
| CN102458418B (zh) | 2015-09-16 |
| US20140140922A1 (en) | 2014-05-22 |
| DK3276004T3 (da) | 2020-04-06 |
| EP2440214A2 (en) | 2012-04-18 |
| US20120141378A1 (en) | 2012-06-07 |
| EP2440214A4 (en) | 2013-07-31 |
| EP3276004A3 (en) | 2018-03-14 |
| JP2012529430A (ja) | 2012-11-22 |
| CN102458418A (zh) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216804A0 (en) | Methods for treating chronic kidney disease | |
| IL257418A (en) | Methods for treating addiction | |
| PL2480255T3 (pl) | Terapia przewlekłych zakażeń jelitowych | |
| IL233017A0 (en) | Methods for treating spinal cord pathologies | |
| PT2440545T (pt) | Compostos úteis para tratar cancro | |
| AP2011005956A0 (en) | Methods of treatment for solid tumors. | |
| GB2475018B (en) | Water treatment methods | |
| GB0822068D0 (en) | Methods for virus design | |
| IL231680B (en) | Activated carbon fiber for treating or preventing kidney disease or dialysis complications | |
| EP2300608A4 (en) | METHODS OF TREATING SOLID TUMORS | |
| EP2621497A4 (en) | ASSOCIATION TREATMENT FOR ROSE ACNE | |
| ZA201204845B (en) | Agents for treating disease | |
| EP2144888A4 (en) | METHODS OF TREATING CANCER | |
| GB201013898D0 (en) | Well treatment | |
| EP2410846A4 (en) | GLYCOLIPIDES AS TREATMENT OF DISEASES | |
| IL213919A0 (en) | Methods to treat cancer | |
| EP2240192A4 (en) | TREATMENT OF DERMATOLOGICAL SUFFERING | |
| IL194373A0 (en) | Methods for treating kidney disorders | |
| IL207906A0 (en) | Treatment for ocular-related disorders | |
| ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
| GB0809046D0 (en) | Cancer treatment | |
| PL2928461T3 (pl) | Leczenie przewlekłej choroby nerek | |
| GB0920940D0 (en) | Agent for treating disease | |
| GB0920942D0 (en) | Agent for treating disease | |
| GB0920933D0 (en) | Agent for treating disease |